Skip to content

Bronchitis and Emphysema Advice and Training to Reduce Hospitalization

CSP #560 - Bronchitis and Emphysema Advice and Training to Reduce Hospitalization (BREATH)

Status
Terminated
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00395083
Acronym
BREATH
Enrollment
426
Registered
2006-11-02
Start date
2006-07-31
Completion date
2010-09-30
Last updated
2014-09-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD, Emphysema

Brief summary

EXECUTIVE SUMMARY: Purpose: To evaluate the efficacy and cost-effectiveness of a novel intervention incorporating self-management education, an action plan, and case-management to decrease the risk of hospitalizations due to chronic obstructive pulmonary disease (COPD) among veterans with severe COPD. Hypotheses: Primary Hypothesis: Veterans with COPD who receive a self-management program incorporating education sessions, development of an action plan, and case-management will have a decreased risk of COPD hospitalization compared to standardized COPD care. Primary Objective: In an intent-to-treat analysis, determine the efficacy of a comprehensive self-management program for reducing the risk of COPD hospitalization in veterans with severe COPD in comparison to patients receiving standardized COPD care. Secondary Hypotheses: Compared with standardized COPD care, veterans with COPD who receive a comprehensive self-management intervention will have: A) decreased health-related costs resulting from decreased hospitalizations and outpatient utilization, B) decreased hospitalization rates and average length of stay due to both COPD and all-cause admissions, and C) improvement in a set of outcomes including mortality, health-related quality of life, medication adherence, patient satisfaction, disease knowledge, skill acquisition and self-efficacy. Secondary Objectives: To evaluate the healthcare costs, hospitalization days, mortality, adherence, and health outcomes of a comprehensive self-management program compared to standardized COPD care among patients with severe COPD measured by: A)Healthcare-related costs B)Health services use due to COPD and to all causes C)Clinical outcome measures 1. Mortality 2. Health-related quality of life measured by generic and COPD-specific measures 3. Patient satisfaction 4. Medication adherence 5. Disease knowledge, skill acquisition and self-efficacy In the proposed study, 960 veterans with severe COPD hospitalized in the previous year will be randomly assigned to either a comprehensive case management program or standardized COPD care. The comprehensive group will receive an initial, intense education program with development of an action plan, and regular telephone contacts by a case manager in addition to standardized COPD care. Patients allocated to the control arm will receive standardized care that incorporates guideline-based recommendations including influenza vaccination, a short-acting bronchodilator, and either a long-acting bronchodilator or inhaled corticosteroid inhaler. The study will be conducted in 2 phases, a 12-month feasibility study conducted at 6 VA sites followed by the full study in which an additional 8 sites will enroll patients over the next 24 months. As a result, 180 patients will be initially enrolled in the feasibility study over the first year and the remaining 780 patients will be enrolled in the second and third years of the study when the full study is implemented. Subjects will be followed until the completion of the study, for at least one, and up to four years. The primary outcome is time to first COPD hospitalization.

Detailed description

EXECUTIVE SUMMARY: Purpose: To evaluate the efficacy and cost-effectiveness of a novel intervention incorporating self-management education, an action plan, and case-management to decrease the risk of hospitalizations due to chronic obstructive pulmonary disease (COPD) among veterans with severe COPD. Hypotheses: Primary Hypothesis: Veterans with COPD who receive a self-management program incorporating education sessions, development of an action plan, and case-management will have a decreased risk of COPD hospitalization compared to standardized COPD care. Primary Objective: In an intent-to-treat analysis, determine the efficacy of a comprehensive self-management program for reducing the risk of COPD hospitalization in veterans with severe COPD in comparison to patients receiving standardized COPD care. Secondary Hypotheses: Compared with standardized COPD care, veterans with COPD who receive a comprehensive self-management intervention will have: A) decreased health-related costs resulting from decreased hospitalizations and outpatient utilization, B) decreased hospitalization rates and average length of stay due to both COPD and all-cause admissions, and C) improvement in a set of outcomes including mortality, health-related quality of life, medication adherence, patient satisfaction, disease knowledge, skill acquisition and self-efficacy. Secondary Objectives: To evaluate the healthcare costs, hospitalization days, mortality, adherence, and health outcomes of a comprehensive self-management program compared to standardized COPD care among patients with severe COPD measured by: A)Healthcare-related costs B)Health services use due to COPD and to all causes C)Clinical outcome measures 1. Mortality 2. Health-related quality of life measured by generic and COPD-specific measures 3. Patient satisfaction 4. Medication adherence 5. Disease knowledge, skill acquisition and self-efficacy In the proposed study, 960 veterans with severe COPD hospitalized in the previous year will be randomly assigned to either a comprehensive case management program or standardized COPD care. The comprehensive group will receive an initial, intense education program with development of an action plan, and regular telephone contacts by a case manager in addition to standardized COPD care. Patients allocated to the control arm will receive standardized care that incorporates guideline-based recommendations including influenza vaccination, a short-acting bronchodilator, and either a long-acting bronchodilator or inhaled corticosteroid inhaler. The study will be conducted in 2 phases, a 12-month feasibility study conducted at 6 VA sites followed by the full study in which an additional 8 sites will enroll patients over the next 24 months. As a result, 180 patients will be initially enrolled in the feasibility study over the first year and the remaining 780 patients will be enrolled in the second and third years of the study when the full study is implemented. Subjects will be followed until the completion of the study, for at least one, and up to four years. The primary outcome is time to first COPD hospitalization. Exacerbations among patients with COPD result in costly emergency room visits and hospitalizations. The overall direct and indirect medical costs of COPD for the United States in 2000 were estimated to be in excess of $30 billion. In the VA health care system, there were 16,073 discharges for COPD in fiscal year 2003 at an average cost of $9,400 (2005 dollars). Disease management programs for COPD may improve patient self-care, improving symptoms and resulting in decreased exacerbations. However, implementing the types of published programs that use self-management education and case-management require additional resources for the VA. The COPD disease management program described in this proposal was developed by extensive modification of existing programs using the strongest theory-based and evidence-based elements, and takes advantage of existing VA systems. By targeting patients at high risk for exacerbations, this study focuses on the population in which the needs and potential impact are the greatest. The intervention is designed to enable patients with COPD to manage their disease more effectively, by monitoring their symptoms and initiating appropriate action when their symptoms worsen. The elements of the program are developed using self-efficacy theory, a recognized and powerful predictor of health-related behavior change. The goal of the intervention is an informed and activated patient working with an informed, skilled case manager to improve self-management of COPD and ultimately clinical outcomes. Case-management programs are used to improve outcomes and to reduce health care utilization among patients with other chronic diseases such as diabetes, congestive heart failure and asthma, suggesting that this approach may be successful in COPD. A study conducted in Canada by Dr. Bourbeau, a co-investigator for this proposal, suggests that an intensive home-based self-management education program and case-management reduce the risk of COPD hospitalizations by 35% over 1-year, and reduced average hospital days by 42%. Cost-savings resulting from decreased hospitalizations offset the cost of the intervention, and the intervention was potentially cost-saving. Relying on home visits, the intervention is not practical or affordable in the VA, and therefore this study evaluates whether a novel case-management intervention for COPD developed specifically for the VA will reduce hospitalizations without increasing overall health-care costs. Because the majority of health care costs for patients with COPD are due to hospitalizations for exacerbations, COPD admissions are the primary outcome and the principal self-management goal. Assessing the cost-effectiveness of this intervention is a critical component of the proposed study, and will provide data for evidence-based decisions by VA physicians and managers regarding the management of COPD.

Interventions

BEHAVIORALCOPD Self-management Education

The comprehensive self-management intervention incorporates self-management education, development of an action plan, and case management. The intervention is designed using the social cognitive theory with the Precede-Proceed Model which has guided other successful patient education programs.

Sponsors

US Department of Veterans Affairs
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No

Inclusion criteria

Population to be studied The study population consists of VA patients with COPD who receive some of their medical care at Veterans Affairs medical centers and were hospitalized for COPD in the last 12 months. To ensure that patients enrolled in the study receive regular care at the participating VA, we will include only patients enrolled in either the primary care or pulmonary clinic at the VA medical center and were seen at least once in the last year. This criterion should not significantly decrease the number of eligible patients because 90% of patients admitted for COPD in the VA had at least 1 outpatient visit to the VA primary care clinic in the year prior to their hospitalization based on data from the VA OPC in FY03. Inclusion Criteria: 1. Diagnosis of COPD confirmed by all of the following: 1. FEV1/FVC \< 0.70 2. FEV1 \< 80% 3. Age \> 40 years 4. A current or past history of cigarette smoking (\> 10 pack-years) 2. COPD hospitalization in the previous year 3. Receives care at participating VA medical center 1. Enrolled in either primary care or pulmonary clinic at the VA 2. Seen at least once in the past year in either primary care or pulmonary clinic 4. No COPD exacerbations in last 4 weeks 5. English-speaking 6. Access to telephone

Exclusion criteria

1. Primary clinical diagnosis of asthma 2. Medical conditions affecting the ability to participate in the study such as: 1. Comorbid illness likely to limit life expectancy \< 1 year 2. Decompensated heart failure 3. Dementia 4. Uncontrolled psychiatric illness 3. Participation in another clinical intervention trial in the previous 30 days

Design outcomes

Primary

MeasureTime frame
Hospitalization-free Survival - Time to EventFrom randomization until date of first hospitalization for COPD, assessed up to 26 months
Hazard Ratio for First COPD Hospitalization26 months

Secondary

MeasureTime frame
Hazard Ratio for All-Cause Mortality26 months
Time to All-Cause DeathFrom randomization until death, assessed up to 26 months

Countries

United States

Participant flow

Recruitment details

The pilot study began in July 2006, and trial recruitment began in January 2007 with 6 sites, later expanding to 20. Recruitment ended early in March 2009 due to DMC recommendations.

Participants by arm

ArmCount
Usual Care
Patients allocated to the control arm will receive standardized care that incorporates guide-line based recommendations including influenza vaccination, a short-acting bronchodilator, and either a long-acting bronchodilator or inhaled corticosteroid inhaler.
217
Comprehensive Care Management Program
The comprehensive group will receive an initial, intense education program with development of an action plan, and regular telephone contacts by a case manager in addition to standardized COPD care. COPD Self-management Education: The comprehensive self-management intervention incorporates self-management education, development of an action plan, and case management. The intervention is designed using the social cognitive theory with the Precede-Proceed Model which has guided other successful patient education programs.
209
Total426

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyDeveloped another disease43
Overall StudyWithdrawal by Subject65

Baseline characteristics

CharacteristicUsual CareComprehensive Care Management ProgramTotal
Age, Continuous65.8 years
STANDARD_DEVIATION 8.2
66.2 years
STANDARD_DEVIATION 8.4
66.0 years
STANDARD_DEVIATION 8.3
Ethnicity (NIH/OMB)
Hispanic or Latino
8 Participants2 Participants10 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
209 Participants207 Participants416 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
5 Participants3 Participants8 Participants
Race (NIH/OMB)
Asian
1 Participants0 Participants1 Participants
Race (NIH/OMB)
Black or African American
20 Participants24 Participants44 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants1 Participants1 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
191 Participants181 Participants372 Participants
Sex: Female, Male
Female
8 Participants5 Participants13 Participants
Sex: Female, Male
Male
209 Participants204 Participants413 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 00 / 0
serious
Total, serious adverse events
98 / 21791 / 209

Outcome results

Primary

Hazard Ratio for First COPD Hospitalization

Time frame: 26 months

ArmMeasureGroupValue (NUMBER)
Usual CareHazard Ratio for First COPD HospitalizationSubjects with COPD Hospitalization34 participants
Usual CareHazard Ratio for First COPD HospitalizationSubjects without COPD Hospitalization183 participants
Comprehensive Care Management ProgramHazard Ratio for First COPD HospitalizationSubjects with COPD Hospitalization36 participants
Comprehensive Care Management ProgramHazard Ratio for First COPD HospitalizationSubjects without COPD Hospitalization173 participants
p-value: 0.6295% CI: [0.7, 1.8]Regression, Cox
Primary

Hospitalization-free Survival - Time to Event

Time frame: From randomization until date of first hospitalization for COPD, assessed up to 26 months

ArmMeasureValue (MEDIAN)
Usual CareHospitalization-free Survival - Time to Event0.45 years
Comprehensive Care Management ProgramHospitalization-free Survival - Time to Event0.46 years
p-value: 0.6295% CI: [0.7, 1.8]Log Rank
Secondary

Hazard Ratio for All-Cause Mortality

Time frame: 26 months

ArmMeasureGroupValue (NUMBER)
Usual CareHazard Ratio for All-Cause MortalityAll-Cause Death10 participants
Usual CareHazard Ratio for All-Cause MortalityAlive207 participants
Comprehensive Care Management ProgramHazard Ratio for All-Cause MortalityAll-Cause Death28 participants
Comprehensive Care Management ProgramHazard Ratio for All-Cause MortalityAlive181 participants
p-value: 0.00395% CI: [1.46, 6.17]Regression, Cox
Secondary

Time to All-Cause Death

Time frame: From randomization until death, assessed up to 26 months

ArmMeasureValue (MEDIAN)
Usual CareTime to All-Cause Death0.51 years
Comprehensive Care Management ProgramTime to All-Cause Death0.49 years
p-value: 0.00295% CI: [1.46, 6.17]Log Rank

Source: ClinicalTrials.gov · Data processed: Mar 26, 2026